Capital Efficiency: It’s not about spending less — it’s about creating value faster

White Papers

For over 30 years we at PharmaVentures have seen the ebbs and flows of venture capital funding into emerging biotech companies. In today’s tight funding environment capital efficiency is again in the forefront of investor and company executive thoughts.

The paper examines how companies can optimise financing strategy, accelerate value creation, and position themselves more effectively for partnering and investment.

 

 

 

Capital Efficiency: It's not about spending less, it's about creating value faster

Download Request

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Dx Deal Review FY 2025: Part 3

White Papers

What does 2026 hold?

Review the final paper in the three-part series to gain deeper

insight into global platform positioning and scalable

diagnostics infrastructure heading into 2026.

Download the full report below.


Dx Deal Review FY 2025: Part 3

Download Request

  • This field is for validation purposes and should be left unchanged.

Dx Deal Review FY 2025: Part 2

White Papers

Collaborations & Alliances in AI and omics gain prominence
in CDx and oncology.

Beyond outright acquisitions, 2025 saw a flood of
partnerships, licensing deals, and co-development
agreements in life sciences diagnostics. These deals are
often the preferred route for accessing novel technology
or entering new markets without full acquisition.

Download the full report below.

 


Dx Deal Review FY 2025: Part 2

Download Request

  • This field is for validation purposes and should be left unchanged.

Dx Deal Review FY 2025: Part 1

White Papers

Major players turn their M&A sights to platforms and technologies with broad application to drive growth.

Gain deeper insight into M&A resurgence and consolidation and strategic consolidation amid tariff uncertainty.

Download the full report below.


Dx Deal Review FY 2025: Part 1

Download Request

  • This field is for validation purposes and should be left unchanged.

How Strategy and Communication Expedite Deal Outcomes

PharmaVentures Podcasts

Adrian Dawkes talks to PharmaVentures' Founder and CEO, Dr Fintan Walton, about the importance of strategy and preparation in today's deal making space. In the competitive, fast-paced environment of deal making within the life sciences industry, if you fail to prepare, then you must prepare to fail. Tune in to help assemble your strategy for success.

About the Presenter: Adrian Dawkes is a Managing Director at PharmaVentures and has been with the company since 2007. Adrian has led multiple consultancy, licensing and M&A mandates. During his professional career, Adrian has significant multi-discipline expertise spanning research and development through to sales, marketing and business development. Adrian has over 30 years' experience in the pharmaceutical, biotechnology and consultancy services sectors. Adrian holds a BSc in Biochemistry and a PhD in Immunochemistry.

Fintan Walton is the Founder and CEO of PharmaVentures. He has over 30 years’ experience helping clients achieve success in deal making. Over a period of three decades, he has built PharmaVentures into a global player in supporting transactions for blue chip corporations and emerging innovator corporations. In that time, the firm has delivered more than 1,000 transaction related assignments for companies in 38 countries.